Estrella Immunopharma, Inc. (ESLA)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.8M) | (613K) | (2.3M) | (2.1M) |
| Net Income | (4.8M) | (613K) | (2.3M) | (2.3M) |
| Diluted EPS | $-0.13 | N/A | $-0.05 | $-0.05 |
Annual Financials
| Metric | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (1.7M) | (11.1M) | (7.3M) | (13.1M) |
| Net Income | (1.7M) | (11.1M) | (7.3M) | (13.1M) |
| Diluted EPS | $-0.05 | $-0.32 | $-0.27 | $-0.35 |